J Gynecol Oncol.
2025 Jan;36(1):e72. 10.3802/jgo.2025.36.e72.
Gynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers
- Affiliations
-
- 1Department of Obstetrics and Gynecology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea
- 2Department of Obstetrics and Gynecology, Daejeon St. Mary’s Hospital, The Catholic University of Korea, Daejeon, Korea
- 3Department of Obstetrics and Gynecology, Uijeongbu St Mary’s Hospital, The Catholic University of Korea, Uijeongbu, Korea
- 4Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 5Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea
- 6Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- 7Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea
- KMID: 2565505
- DOI: http://doi.org/10.3802/jgo.2025.36.e72
Abstract
- This review summarized the results of clinical trials in 2024 that were believed to have a significant impact on clinical practice in the field of gynecologic oncology. The SHAPE trial, INTERLACE and KEYNOTE-A18 trials, and BEATcc and COMPASSION-16 trials were included in early-stage, locally advanced, and recurrent/metastatic cervical cancer, respectively. For uterine corpus cancer, updated survival data of the four trials (NRG-GY018, RUBY, AtTEnd, DUO-E) for endometrial cancer and the first survival data of LMS-04 trial for leiomyosarcoma were described. For ovarian cancer, the final overall survival results of PRIMA study were followed by DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 trial in different disease conditions. Finally, the results of DESTINY-PanTumor02, a basket trial of trastuzumab deruxtecan, were briefly addressed.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Analysis of Gynecologic Cancer Registry in Chungnam National University Hospital for 10 years
- Advanced ovarian cancer: what should be the standard of care?
- Evolving strategies for ovarian cancer: gynecologic oncology in ASCO's 46th annual meeting
- Current status in the management of uterine corpus cancer in Korea
- Current status of gynecologic cancer in Japan
